Skip to main content
. 2021 Aug 10;20(10):1904–1915. doi: 10.1158/1535-7163.MCT-20-0638

Figure 5.

Figure 5. Itraconazole inhibits OE33-derived tumor xenograft growth. A, NOD-SCID mice were injected subcutaneously with 5 × 106 OE33 cells. When tumors formed, mice were randomly divided into 2 groups (control and itraconazole, n = 8). The mice were treated with placebo or itraconazole (80 mg/kg) by oral gavage twice daily for two consecutive weeks. B, Concentrations of itraconazole and its primary metabolite hydroxyitraconazole in esophagi and tumor xenografts from mice treated with placebo or itraconazole. C, Western blot analysis of p-AKT, AKT, p-S6, S6, HER2, p-AMPK, and AMPK expression in OE33-derived xenografts treated with PBS or itraconazole for two weeks. GAPDH is used as a loading control. D, Representative IHC staining of p-S6 from xenograft sections treated with placebo or itraconazole. Scale bar, 100 μm.

Itraconazole inhibits OE33-derived tumor xenograft growth. A, NOD-SCID mice were injected subcutaneously with 5 × 106 OE33 cells. When tumors formed, mice were randomly divided into 2 groups (control and itraconazole, n = 8). The mice were treated with placebo or itraconazole (80 mg/kg) by oral gavage twice daily for two consecutive weeks. B, Concentrations of itraconazole and its primary metabolite hydroxyitraconazole in esophagi and tumor xenografts from mice treated with placebo or itraconazole. C, Western blot analysis of p-AKT, AKT, p-S6, S6, HER2, p-AMPK, and AMPK expression in OE33-derived xenografts treated with PBS or itraconazole for two weeks. GAPDH is used as a loading control. D, Representative IHC staining of p-S6 from xenograft sections treated with placebo or itraconazole. Scale bar, 100 μm.